Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06800066 · ClinicalTrials.gov registry record · NA
RCT-Consumer Perceptions of Cannabidiol (CBD) Health Claims
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 460
- Enrollment target
NCT06800066: Completed NA study, sponsored by Wake Forest University Health Sciences.
NCT06800066 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 460 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06800066, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 460 participants
- Enrollment target
Study Summary
Cannabidiol (CBD) cannot be marketed as having therapeutic benefits (without FDA's approval), be false or misleading to consumers, or convey the products are approved or endorsed by the FDA. In addition, CBD cannot be marketed as a food additive or dietary supplement since it is an active ingredient in an approved drug, Epidiolex. Despite this, CBD products have been illicitly advertised to consumers with these claims including unsubstantiated health claims that promote benefits including curing cancer and preventing Alzheimer's disease. These types of claims may be influencing consumers to use CBD. This study aims to examine the impact of CBD advertising with health claims on consumer purchase behavior.
Primary Outcome
The primary outcome is purchase of a CBD product. The percent of participants who purchase at least one CBD product in each group (CBD ads vs non-CBD ads) will be reported.
Interventions
- BEHAVIORAL Purchase Behavior - (Non-CBD ads)
- BEHAVIORAL Purchase Behavior - (CBD ads)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2025-01-08 |
| Est. Completion | 2025-08-15 |
| Phase | NA |
What the finished NCT06800066 record still lists
NCT06800066 is an interventional study that assigns participants to a tested intervention. The registered 460 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 2 interventions - of which Purchase Behavior - (Non-CBD ads) is the first listed.
NCT06800066 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06800066 about?
NCT06800066 is a clinical study titled "RCT-Consumer Perceptions of Cannabidiol (CBD) Health Claims". Cannabidiol (CBD) cannot be marketed as having therapeutic benefits (without FDA's approval), be false or misleading to consumers, or convey the products are approved or endorsed by the FDA. In addition, CBD cannot be marketed as a food additive or dietary supplement since it is an active ingredient...
What is the current status of trial NCT06800066?
This trial is currently completed. It is a NA study. The enrollment target is 460 participants. The study started on 2025-01-08. Estimated completion is 2025-08-15.
What interventions are being tested in trial NCT06800066?
The interventions under investigation include: Purchase Behavior - (Non-CBD ads) (BEHAVIORAL), Purchase Behavior - (CBD ads) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06800066?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06800066's enrollment target sits among peer trials
460 222nd of 2000 higher than 1,777 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
- NCT04621279 · 460 participants
Cool Prime Comparative Effectiveness Study for Mild HIE
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI